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1. Introduction 
The metastatic spread of solid tumors is the most fatal complication in malignant diseases 
and the major cause of tumor-related mortality. This is of high relevance for malignant 
melanoma which are highly proliferating tumors with aggressive metastatic tendency. The 
majority of melanoma cells tend to metastasize primary via the lymph system and 
secondary into different organs, most likely distant skin regions, liver, lungs, brain, and 
heart via hematogenous distribution, which is associated with bad prognosis. The molecular 
mechanisms of the metastatic processes are complex and not fully elucidated. Although 
cytostatic agents or anti-angiogenetic drugs (e.g. Avastin/bevacizumab) affect, beside their 
effects on the primary tumors, also the growth and development of metastases, there is at 
present no antimetastatic pharmacological strategy in the clinics to interfere with tumor cell 
dissemination or spread. 
Adhesion receptors are strongly involved in the process of tumor cell metastasis, either by 
deregulation of adhesive functions and subsequently the detachment of tumor cells from the 
primary tumor and the overcoming of tissue borders, or by mediating manifold cell contacts 
with blood components in the phase of hematogenous distribution. An intensive and 
ongoing preclinical research provided essential insight and several postulated factors and 
mechanisms for the hematogenous dissemination, i.e. the interaction of tumor cells with the 
different blood elements, soluble factors and cells. P- and L-selectin, members of a family of 
carbohydrate binding adhesion receptors are regarded as functional key players in the 
contact formation of tumor cells with platelets and leukocytes, thus facilitating microemboli 
formation and accelerating metastatic dissemination. The antimetastatic activities of 
heparin, confirmed by a number of prospective clinical trials, are to a large extent ascribed 
to the inhibition of these two selectins.  
Besides the important role of selectins, integrins as ubiquitary cell adhesion receptors are 
also involved in the mediation of manifold adhesive interactions in the metastasis of tumor 
cells. Integrins bind ligands of the extracellular matrix (ECM), such as fibronectin, collagen, 
laminin and vitronectin to stabilize cell attachment with the surrounding tissues or to 
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mediate migration in the metastatic cascade. Furthermore, integrins mediate cellular 
contacts of the tumor cells to platelets, leukocytes, and endothelium. However, in contrast to 
the selectins, the integrin function has hardly been considered as target for antimetastatic 
approaches.  
Integrins possess important tasks in cell signalling that can be summarized as defining the 
cellular shape, mobility, invasion and cell cycle regulation. The regulation of these processes 
via contribution of the actin and microtubule cytoskeletons is well known to be controlled 
by Rho-GTPases (Ras homologue; guanosintriphosphatases), which belong to the 
superfamily of Ras-GTPases (Rat adeno sarcoma). GTPases of the Ras-superfamily are 
important for cell proliferation, metastasis, migration, apoptosis, gene expression and 
multiple other functions in the cell. Since the integrin signalling is also cross-linked to the 
function of GTPases, a therapeutic influence on the GTPase activity could be a novel and 
attractive approach to control integrin bindings. Recent data on the treatment of melanoma 
cells with lysophosphatidylcholine (LysoPC) referred to reduced integrin functions, which 
might be related to reduced GTPase signalling.  
This book chapter will deal with the molecular function of adhesion receptors in the process 
of hematogenous metastasis of melanoma cells and the therapeutic potential and prospects 
to interfere with adhesion receptor activity as an antimetastatic approach. The focus was put 
on the integrins, which will be explained with their functions, abilities and connections to 
other indispensable proteins, such as cytoskeletal components in the context of cancer and 
metastasis. Finally the hypothesis to influence the integrin functions in metastatic cascade at 
a signalling level will be introduced and discussed as an interesting novel target for 
antimetastatic approaches. 
2. The metastasis of melanoma cells 
2.1 The course of the metastatic cascade  
Tumor cell metastasis is a complex cascade which consists of various molecular events. 
Metastatic cells have to exit the primary tumor by a deregulation of the cellular contacts, 
have to migrate the basement membrane of the tumor, degrade the extracellular matrix and 
intravasate lymphatic vessels or local post capillary veins. Several factors are known which 
contribute to the malignant transformation of melanocytes and melanoma development and 
progression, including microenvironmental influences, or UV radiation for triggering a 
cascade of proinflammatory factors and mediators (Lee & Herlyn 2006; Schwarz & Luger 
1989).  
Once in the blood system, the tumor cells have to escape the immune surveillance and 
physical stress of the blood stream to finally seed at the vascular bed at distant organs. This 
is the rate-limiting step of the metastatic cascade before they can extravasate and form 
metastases (Figure 1).   
An insight into the hematogenous phase of tumor cell distribution is given by numerous 
animal models of experimental metastasis, which dominantly used melanoma cell lines due 
to their rapid metastatic colonization tendency (Ludwig et al., 2004; Bereczky et al., 2005; 
Ludwig et al., 2006; Mousa et al., 2006; Niers et al. 2009). Although these models do not 
completely recapitulate the natural processes of metastatic spread, the timely defined 
presence of tumor cells in the blood systems allows for characterization and evaluation of 
cellular contacts within the phase of hematogenous distribution.  
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Fig. 1. Schematic representation of the hematogenous metastasis.  
The illustration give insights into the step-by-step process of the hematogenous metastasis: 
Detachment of tumor cells from primary tumor; overcoming of ECM, intravasation into the 
blood system, association with platelets and leukocytes to prevent shear forces and immune 
defense, transport through the organism, physical arrest or arrest via interaction with the 
vascular endothel, extravasation, generation of micrometastases and angiogenesis to the 
blood supply.  
Modified from (Guo W. & Giancotti F. G., 2004) 
The massive interaction of tumor cells forming a platelet cloak is a vital strategy to evade the 
immune defense and was shown to correlate with metastatic progression. Furthermore, the 
recruitment of leukocytes to form microemboli is thought to support microvascular arrest at 
distant sites and contributes to activation of endothelial cells. In general, tumor cell and/or 
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leukocyte interaction with the microenvironment at site of colonization induces an 
inflammatory-like activation of endothelial cells during the initial steps of metastasis 
progression, including the chemokine network and different procoagulative factors 
(Lazennec & Richmond, 2010). However, cellular adhesion receptors play a pivotal role for 
this complex cellular communication.  
2.2 The impact of selectins on the hematogenous tumor cell dissemination 
The selectins, a family of carbohydrate binding proteins, represent the crucial importance 
linked with hematogenous metastasis (Läubli & Borsig, 2010). P-selectin, expressed by 
platelets is dominant for the platelet contact of tumor cells. Its role for protecting the tumor 
cells and facilitating metastatic progression is confirmed by experiments using P-selectin 
knock-out mice, which displayed strongly attenuated experimental metastasis (Ludwig et al., 
2004; Kim et al., 1998). It became evident that P-selectin, expressed by activated endothelial 
cells also contributes to the metastatic progression (Ludwig et al., 2004). L-selectin, which is 
constitutively expressed by all types of leukocytes, supports the comprehension of leukocyte 
into the microemboli and vascular contact formation and activation (Laubli et al., 2006). 
Endothelial activation is associated with the upregulation of other adhesion receptors, such as 
E-selectin or the integrin ligand vascular cell adhesion molecule-1 (VCAM-1), which again 
advises to the inflammatory-like reaction (Auguste et al., 2007).  
Consequently, the competitive blocking of the selectin function appears as a promising 
therapeutic approach to interfere with the metastatic cascade.  
2.3 The role of heparin for antimetastatic approaches 
The evidence for those selectin-blocking approaches came indirectly from clinical efforts to 
treat cancer-associated thromboembolic events, which are frequent complications in 
malignant diseases. Heparin, or low molecular weight heparin (LMWH) are the 
anticoagulant drug of choice in the clinical treatment or prophylactic treatment of cancer-
associated thrombosis. Based on the retrospective evaluation of clinical data, which referred 
to a survival benefit of heparin treated cancer patients, a number of prospective clinical 
trials have been lauchned (Zacharski & Lee, 2008). Animal experiments supported the 
assumption that heparin hardly affects the primary tumor but interferes with the process of 
metastasis. Several molecular mechanisms exist to explain the antimetastatic efficiency of 
heparin. The reader is referred to excellent reviews in this field (Borsig, 2010; Casu et al. 
2008) from which the inhibitory capacity of heparin towards P- and L-selectin binding 
should be highlighted here. 
Heparin as a highly sulfated, acidic polysaccharide has the ability to compete with the natural 
mucin-like selectin ligands. The capacity of heparin to interfere with P- and L-selectin binding 
has already been described in the early 90th (Skinner et al., 1991), but in the context of tumor 
cell metastasis the heparin effects as competitors of P- and L-selectins were accumulated 
during the last decade. Further insight was obtained into the structural requirements of 
heparin for selectin binding (Hostettler et al., 2007), and binding affinities of heparin to both 
selectins were shown to be in the low micromolar range (Simonis et al., 2007). 
2.4 Integrins as targets for heparin 
The platelet integrin IIb IIIa also contributes to the bond formation between platelets and 
melanoma cells via fibronectin or vWF to melanoma integrins. A recent study reported that 
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heparin has also an inhibitory capacity to this binding (Zhang et al., 2009). Thrombin, 
interacting with its receptor PAR-1 on melanoma cells (protease-activated receptors-1) has a 
strong impact for regulating this interaction. PAR-1, which is predominantly overexpressed 
in malignant melanoma cells induces diverse procoagulant and metastatic events, such as 
matrix degradation, secretion of angiogenetic factors or integrin activation (Melnikova et al., 
2008).  
Melanoma integrins can also directly contribute to the firm adhesion to the vasculature. The 
integrin 41 (very late activation antigen-4, VLA-4), which interacts with the VCAM-1 as 
counter receptor, is described as another pathway for endothelial arrest of malignant 
melanoma cells (beside osteosarcoma and rhabdomyosarcoma cells), thereby promoting the 
transmigration (Okahara et al., 1994; Liang & Dong, 2008) and metastasis (Garofalo et al., 
1995; Schadendorf et al., 1995). Although these finding suggest that the inhibition of VLA-4 
could be promising in the treatment of melanoma metastasis, and despite VLA-4 inhibition 
by antibodies or small molecules is a vital strategy to interfere with pathological 
inflammations, such approaches have not been described so far in the cancer field. We could 
recently show that the VLA-4/VCAM-1 interaction of murine or human melanoma cell lines 
can be efficiently blocked by heparin (Schlesinger et al., 2009). Nevertheless, beside those 
approaches for a competitive blockade of integrin receptor function, the manifold signalling 
functions of integrins open a new way for a therapeutic interference, which will be 
discussed below.   
3. The biology of integrins in the context of cell adhesion processes and 
metastasis 
In addition to the selectin-mediated cell adhesion processes in metastasis, the protein 
families of immunoglobulins (IGs), cadherins and integrins play important roles – in the 
case of malfunction - in the development and progression of melanoma metastasis.  
Several members of the IG superfamily such as ICAM-1, L1CAM and MCAM/MUC18 are 
significantly associated with progression of melanoma metastasis (Meier et al., 2006; Yamada 
et al., 2006; Johnson et al., 1997). The MUC18/MCAM expression confers metastatic potential 
and increased tumorigenicity to human melanoma cells (Johnson et al., 1999). A switch of the 
cadherin molecules from E-cadherin to N-cadherin is responsible for the disassociation of 
melanoma cells from keratinocytes. The loss of E-cadherin function is connected with the 
upregulation/induction of MUC18/MCAM and v3 integrin in melanocytic cells in vitro 
and with changes in the levels and the cellular distribution of the transcriptional regulator -
catenin in melanomas in vivo (Johnson et al., 1999). Thus, melanoma cell invasion through the 
dermis is mediated by this change (Hsu et al., 1996; Hsu et al., 2000).  
One of the most prominent examples that is frequently associated with the progression of 
melanoma is the integrin 41 (VLA-4) (Braeuer et al, 2011). It was observed that VLA-4 
overexpression and interaction with VCAM-1 is clearly correlated with experimental lung 
metastasis and the tumor stage (Schadendorf et al., 1995; Okahara et al., 1994). Due to the 
fact that the interaction of VLA-4 and VCAM-1 and other integrins are of great interest as 
possible targets for melanoma cancer therapy, the following chapter will handle with details 
on the integrin family and their structural and functional connections in the context of 
cancer metastasis. 
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3.1 The general structure of integrins 
The integrins are large and complex transmembrane glycoproteins which act as adhesion 
receptor molecules that are responsible for the mediation of attachment and anchorage 
between cells or to the underlying extracellular matrix (ECM) (Morgan et al., 2007). In detail 
they span the plasma membrane and work alongside other proteins such as cadherins and 
selectins to mediate cell-cell and cell-matrix interaction and communication. One important 
task of integrins is the binding of the cell surface and ECM components such as fibronectin, 
vitronectin, collagen, and laminin.  
Many cells have multiple types of integrins on their surface. That means the use of integrin-
targeted reagents is not specific for all but for a few or one specific integrin. This provides 
additional mechanistic insights into the functions of integrin adhesion receptors.  
The structure of integrins can be divided in two distinct chains, the ǂ- and ǃ-subunit (Figure 
2) which form a non-covalent heterodimer (Morgan et al., 2007; Lau et al., 2009; Shattil et al., 
2010). In mammals, 18 ǂ- and 8 ǃ-integrin genes have been characterized that encode 
polypeptides that combine to form 24 unique, canonical ǂ/ǃ receptors out of 144 possible 
combinations. The Drosophila genome encodes only five ǂ- and two ǃ-subunits, and the 
Caenorhabditis nematodes possess two ǂ and one ǃ genes (Shattil et al., 2010; Morgan et al., 
2007; Humphries, 2000). In addition, variants of some integrin subunits are formed by 
differential splicing, for example four variants of the beta-1 subunit exist (Hynes, 2002).  
Both the ǂ- and ǃ-subunits form separate tails, which penetrate the plasma membrane and 
possess small cytoplasmic domains (Nermut et al., 1988; Lau et al., 2009). The extracellular 
ǂ/ǃ-domains are relatively huge compared to the short cytoplasmic domain and the 
structure of each subunit is conserved between isoforms, excluding a subset of ǂ-subunits, 
which include an inserted ‘A-domain’ in their ligand-binding pocket (Shattil et al., 2010; 
Morgan et al., 2007). The pathway of extracellular binding of integrins to intracellular 
transformation of the binding is most often mediated by the cytoplasmic tail of the ǃ-
subunit (Morgan et al., 2007).  
3.2 The cellular functions of integrins 
Concerning the function, integrins are involved in a wide range of biological activities, 
including immune patrolling, cell migration, defining cellular shape, cell cycle regulation, 
growth, invasion, proliferation, differentiation, survival/apoptosis and binding to cells by 
certain viruses (Desgrosellier & Cheresh, 2010; Assoian & Klein, 2008).  
The integrin proteins act as receptors which are able to communicate between the ECM and 
the cell. They also transport information from the status inside the cell to the extracellular 
space. This allows rapid and flexible responses in both directions. Thus integrin tasks can be 
divided into two main functions: Attachment of the cell to the ECM and signal transduction 
from the ECM to the cell. Within the past decade it has become apparent that adhesion 
molecules such as integrins play an important role for the mediation of critical cytosolic 
signalling events in the cell (Stupack, 2007).  
Integrins act to regulate complex processes in cancer disease such as angiogenesis, tumor 
growth and metastasis (Hynes, 2002), and the signalling has a dramatic impact on cell 
proliferation, survival and motility. For this reason they have become attractive therapeutic 
targets for the development of pharmaceutical compounds. Several effective integrin 
antagonists are now under clinical evaluation (Stupack, 2007).  
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Fig. 2. Domain architecture of the heterodimeric transmembrane domains which show how 
integrins are designed to act as bidirectional signalling machines. Integrins are 
heterodimeric adhesive receptors consisting of an ǂ- and a ǃ-subunit. The ligand binding 
site is provided by the N-terminal domain of the ǂ- and ǃ-integrin subunits (the ǃ-propeller 
and the ǃA domain, respectively) which are assembled in most integrins by non-covalent 
interactions to form a “head”. It is known that in 8 ǂ integrin subunits (ǂ1, ǂ2, ǂ10, ǂ11, ǂL, 
ǂM, ǂX and ǂD), the ǂA domain, which is homologous to the ǃA domain of the ǃ-integrin 
subunit, is inserted into the ǃ-propeller domain. This is the main ligand-binding site in these 
integrins. Integrins that lack an A domain (e.g. the depicted schematic architecture of ǂIIbǃ3 
integrin), the ǃA domain forms the main ligand-binding site. The PSI-domain (plexin, 
semaphorin and integrin) is at the N terminus of the ǃ-integrin subunit, but is joined by 
disulfide bonds to more C-terminal residues. The remaining C-terminal extracellular 
domains of the ǂ- and ǃ-subunit comprise two long ‘legs’ which are anchored in the PM. 
The low affinity state of the integrin for its ligands is maintained by non-covalent 
interactions between the ǂ- and ǃ-integrin transmembrane and cytoplasmic domains. Figure 
is modified from (Shattil et al., 2010); ǂ-subunit and ǃ-subunit 
In particular integrins operate as mechanistic biosensors in a context-dependent manner. On 
one hand, integrins that ligate substrate-immobilized ligands typically transduce positive 
signals into the cell. On the other hand, antagonized or unligated integrins promote negative 
signalling into the cell, which leads to cell cycle arrest or apoptosis. Thus, integrins constantly 
interrogate the local ECM and modulate cell behaviour accordingly. Typically, receptors 
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inform a cell of the molecules in its environment and the cell evokes a response. Integrin 
receptors have two ways of signalling. They are able to perform outside-in signalling - 
response to molecules in its environment - and they also operate in an inside-out mode 
(Huveneers & Danen, 2009; Shattil et al., 2010; (Figure 3)). Therefore they are known as 
bidirectional, allosteric molecular signalling machines, although the relationship between 
specific conformations and activation remains controversial (Hynes, 2002; Shattil et al., 2010).  
 
 
Fig. 3. Cellular signalling modes of integrins. 
The two ways of integrin signalling can be divided in “outside-in” (left) and “inside-out” 
(right) modes. Both directions have different biological and biochemical consequences. In 
the case of “outside-in” signalling, binding of integrins to their extracellular ligands changes 
the conformation of the integrin and - because many of the ligands are multivalent - 
contributes to integrin clustering. The combination of these two events leads to intracellular 
signals that control cell polarity, cytoskeletal structure, gene expression, cell survival and 
proliferation. During ‘inside–out’ signalling, an intracellular activator, such as talin or 
kindlins, binds to the ǃ-integrin tail, leading to conformational changes that result in 
increased affinity for extracellular ligands (integrin ‘activation’). Inside–out signalling 
controls adhesion strength and enables sufficiently strong interactions between integrins 
and ECM proteins to allow integrins to transmit the forces required for cell migration and 
ECM remodelling and assembly. Both modes of signalling are often closely linked; for 
example, integrin activation can increase ligand binding, resulting in outside–in signalling. 
Conversely, ligand binding can generate signals that cause inside–out signalling.  
Modified from (Shattil et al., 2010) 
www.intechopen.com
The Role of Adhesion Receptors in Melanoma  
Metastasis and Therapeutic Intervention Thereof 
 
401 
As mentioned before, the cytoplasmic tail of the ǃ-subunit is known to be the main region of 
mediating protein interaction (e.g. talin, a cytoskeletal protein), signal transduction and 
direct integrin activation (Shattil et al., 2010; Morgan et al., 2007).  
4. The integrins in the context of signal transduction processes 
The mechanisms of integrin interaction at the cytoplasmic side are strongly connected to the 
regulation of GTPases. For example, activated Rac1 and RhoA transduce signals to integrin 
activation via phospholipase D (PLD) and phosphatidylinositol-4-phosphate 5-kinase 1γ 
(PIP5K1γ) (Tybulewicz & Henderson, 2009). Furthermore it is known that integrin signalling 
is inhibited by RhoH through an unknown mechanism. In this case, integrin signalling leads to 
the activation of the GEF αPIX (PAK-interacting exchange factor-α) and the following 
activation of Rac1 and PAK (p21-activated kinase) (Tybulewicz & Henderson, 2009). PAKs are 
well known to serve as targets for the small GTPases Cdc42 and Rac and they have been 
implicated in a wide range of biological activities, such as regulating the cell motility and 
morphology (PAK1), involvement in apoptotic processes (PAK2), or in the rapid cytoskeletal 
reorganization in dendritic spines (PAK3) or mediation of filopodia formation (PAK4).  
Integrin signalling works predominantly through the recruitment and activation of Src-family 
kinases (SFKs). Most integrins recruit focal adhesion kinase (FAK) through their cytoplasmic 
domain of the ǃ-subunit (Guo & Giancotti, 2004). FAK works as a phosphorylation-regulated 
scaffold to recruit Src to focal adhesions. From this important point of origin, several signal 
pathways influence the cell proliferation, survival and migration (Figure 4). Activating 
signalling via FAK, phosphatidylinositol 3-kinase (PI3K) over phosphatidylinositol-3,4,5-
trisphosphate (PtdIns(3,4,5)P3) to AKT and protein kinase B (PKB) can induce the mentioned 
effects (e.g. adhesion, cell proliferation, etc.). In addition, there is a direct crosstalk via GEF to 
activate Rac (another possibility for activation is from SFK via CAS, Crk and DOCK180 to Rac) 
which in turn can activate PAK, Jun amino-terminal kinase (JNK) and nuclear factor kappa-B 
(NFκB) (Parsons & Parsons, 1997; Schlaepfer & Hunter, 1998; Cary et al, 1999). Furthermore 
FAK can activate extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) by recruiting the Rap1 GEF C3G through Crk. Rap1 is then able to activate 
ERK/MAPK through B-Raf. An alternative way for ERK/MAPK activation is via the direct 
recruitment of growth-factor-receptor-bound-2 (GRB2) and son-of-sevenless (SOS) complex. 
Here, certain integrins, including ǂ5ǃ1, ǂ1ǃ1 and ǂvǃ3, are coupled to palmitoylated SFKs 
through their ǂ-subunits. The palmitoylated SFKs recruit and phosphorylate the adaptor Shc, 
which combines with GRB2–SOS to activate ERK/MAPK signalling from Ras (Wary et al., 
1996; 1998).  
Beside the interaction of integrins with SFKs mentioned before, some integrins are able to 
interact directly with SFKs via the cytoplasmic tail of their ǃ-subunits (Arias-Salgado et al., 
2003). As an example, the ǂ6ǃ4 integrin is palmitoylated at its ǃ-subunit. This 
palmitoylation is required for the incorporation of the complete ǂ6ǃ4 integrin in lipid rafts 
where the receptor is able to interact with SFKs that are similarly palmitoylated (Gagnoux-
Palacios et al., 2003). Here, the SFKs phosphorylate several tyrosine residues in the 
cytoplasmic domain of ǃ4, which causes the recruitment of SHC and activation of Ras–
ERK/MAPK and PI3K signalling (Mainiero et al., 1995; 1997; Shaw et al., 1997; 2001). The 
known pathways that integrins can activate through SFKs are sufficient for the induction of 
cell migration, invasion and proliferation or to confer some protection from apoptosis on 
cells.  
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Fig. 4. General overview of alternative integrin signalling pathways.  
The figure shows a section of the possible signalling cascades which lead to the activation of 
cellular survival proliferation and migration. Further details to the interactions are 
explained in the main text.  
Modified from (Guo & Giancotti, 2004).  
In addition to the ǂ6ǃ4 integrin, ǂ4ǃ1 (VLA-4) and ǂLǃ2 have been identified to colocalize 
with the lipid raft marker GM-1 in T-cells. Disruption of raft integrity through depletion of 
membrane cholesterol with methyl--cyclodextrin (MbCD) completely disrupted ǂ4ǃ1 
cluster formation, implying that the lipid rafts are required for ǂ4 integrin clusters (Leitinger 
& Hogg, 2002). The integrins ǂvǃ3, ǂIIbǃ3 and ǂ2ǃ1 are associated with specific integrin 
interacting proteins in cholesterol-dependent microdomains distinct from classical rafts 
(Green et al., 1999). These results hypothesize that the mechanism of membrane 
compartmentalization – as identified for the mentioned integrins – also operates in other 
integrin-signalling systems, which might be an explanation for several specific aspects of 
diverse integrins.  
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5. Possible ways for pharmacological antimetastatic approaches by 
intervention with integrins on the plasma membrane and signalling level 
The integrins, especially the integrin VLA-4 has been for longer time in the interest as target 
for the design of small molecule competive inhibitors as potential antiinflammatory drugs 
(Singh et al, 2004).  
Concerning the “non-competitive” influence on integrins, there basically exist two different 
ways for integrin modulation: An interference with the signal transduction at the 
cytoplasmatic site or an influence on the integrin compartmentalization at the plasma 
membrane. As mentioned before the influence on integrins is mainly mediated via the 
cytoplasmatic tail of their ǃ-subunits which allows the inside-out signalling (Arias-Salgado 
et al., 2003).   
In general, integrins essentially need the specific membrane positioning and membrane 
anchorage of signalling proteins like GTPases of the Ras-superfamily for their signalling 
processes. The distribution of Ras proteins is determined by different C-terminal lipid 
modifications. Extensive experimental studies on Ras-GTPases have revealed that the 
proteins only operate at the plasma membrane (Meder & Simons, 2005; Pechlivanis & 
Kuhlmann, 2006). Several publications have pointed out the importance of Ras 
compartmentalization for signal transduction (Roy et al. 2002; Chiu et al., 2002). In 
particular, the palmitoylation allows the anchorage for H-Ras / N-Ras and the spatial and 
temporal organization plus segregation of the GTPases signal transfer duration. The time of 
PM-Golgi apparatus cycling, for N-Ras the transfer time from the PM to the Golgi apparatus 
during cycling, was remarkably shortened compared to H-Ras (Rocks et al., 2010; Rocks et 
al., 2005). This is in line with their palmitoylation status – two palmitoyl anchors for H-Ras 
and one palmitoyl anchor for N-Ras. Therefore, impact on the GTPase localization by 
affecting the membrane characteristics might have strong consequences for the integrin 
activity too. 
In addition to the ǂ6ǃ4 integrin mentioned before, which possesses as laminin-5 receptor 
unique functions in epithelial growth and carcinoma invasion (Mainiero et al., 1997; Shaw et 
al., 1997) a palmitoylation of the ǃ4-subunit as a prerequisite for the incorporation of ǂ6ǃ4 in 
rafts and the compartmentalization with SFKs  (Gagnoux-Palacios et al., 2003), other 
integrins were also reported to depend critically on their membrane localization. The ǂ4ǃ1 
integrin (VLA-4) was also identified to be localized in lipid rafts, which revealed that lipid 
rafts also play a key role in regulating integrin activity, function and its further downstream 
signalling (Leitinger & Hogg, 2002; Schadendorf et al., 1995; Okahara et al., 1994). Non-raft 
integrins are excluded from the rafts by cytoskeletal constraints and are no more able to 
perform signalling from raft microdomains (Leitinger & Hogg, 2002). Thus, the positioning 
of integrins inside or outside of rafts for their physical interaction with important signalling 
switches, such as GTPases or FAKs depends critically on the surrounding lipid composition. 
Consequently, an influence on the membrane characteristics and lipid composition of tumor 
cells appears as attractive way to influence integrin activities. 
In a recent study, such an aspect of attenuated melanoma metastasis has been reported 
(Jantscheff et al., 2011), which refers to reduced receptor mediated binding by non-
competively interfering with integrin function. This study is based on earlier findings that 
empty liposomes consisting of saturated phosphatidylcholine (PC) displayed strong 
antimetastatic effects in a murine pancreatic mice model (Graeser et al., 2009). Jantscheff et 
al. (2011) postulated that liposomes, passively accumulated in the tumor, release LysoPC as 
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a degradation product of the saturated PC which affects the capability of tumor cells for 
metastases. In order to follow this hypothesis, the authors incubated murine melanoma 
B16.F10 cells with physiological and increased concentrations of saturated LysoPC. The 
melanoma cells fastly removed the LysoPC from the medium which was accompanied by a 
radical shift in tumor cell membrane fatty acid composition towards saturated fatty acids. 
This had strong morphological and functional consequences for the tumor cells. Electron 
microscopic images suggested that the changed membrane composition leads to a strong 
increase in number and size of filopodial-like membrane protrusions. It became evident that 
these morphological changes are based on cytoskeletal contractions. However, these 
concentrations of LysoPC used did not possess direct cytotoxicity. An induction of apoptosis 
could also be excluded.  
The functional basis for antimetastatic effects of LysoPC became exposed by investigating 
the adhesion receptor binding. As mentioned before, melanoma cells make use of their 
integrin VLA-4 binding the endothelial ligand VCAM-1 for vascular arrest in the metastatic 
cascade. LysoPC incubation affected crucially the VLA-4 activity in a concentration 
dependent manner, although the expression levels of this integrin were not changed. 
Exceeding the physiological LysoPC concentration, the melanoma cells lost their ability for 
VCAM-1 binding. Furthermore, even though the treated cells exhibited a remarkably 
augmented number of protrusions, the cell motility on fibronectin as essential requirement 
for distinct steps of metastasis, e.g. tissue transmigration was significantly attenuated. In 
addition, the interaction with platelets via P-selectin was also strongly diminished, which is 
a further factor for reduced metastasis. These in vitro findings were totally reflected in a 
syngenic intravenous lung-invasion model. Using ex vivo-treated B16.F10 cells, LysoPC 
concentrations above the threshold (450 µM) resulted in significantly reduced metastasis-
like lesions in lung tissue.  
The search for the molecular basis of these promising data is ongoing yet, but might lead to 
some preliminary postulations. On the one hand, biophysical aspects of membrane 
properties and their change by the saturated lipids can be discussed to affect integrin 
function. On the other hand, an interference of LysoPC with the integrin signalling at the 
level of GTPases can be assumed.  
Referring to the first assumption, a balance between saturated and unsaturated fatty acids is 
a fundamental biophysical determinant of membrane fluidity (Mansilla et al., 2008). The so-
called homeoviscous adaptation is highly regulated and influences important membrane 
properties as flexibility, and lipid raft composition (Mansilla et al., 2008; Stulnig et al., 2001; 
Callaghan et al., 1993; Hac-Wydro et al., 2007). This strongly indicates that the addition of 
exogenous fully hydrogenated LysoPC and the subsequent change of membrane 
composition might have a clear impact on the deregulation of these factors. Since the 
integrin function is dependent on several aspects of membrane compartmentation (as 
described before), a reduced VLA-4 function could result from changes in e.g. raft domains.  
Concerning the expression of important signalling proteins, we observed slightly reduced 
gene expression of the GTPases RhoA, RhoB and others after LysoPC exposition (300 µM 
and 450 µM) indicating an altered signal transduction in the context of membrane shape and 
adhesion (Alexander M. et al., 2010; 2011). RhoA and RhoB are known to participate in the 
regulaton of cytoskeleton, proliferation, formation of filopodia, lamellipodia, stress fibers 
and adhesion complexes (Hall A., 1998; Bishop & Hall, 2000; Etienne-Manneville & Hall, 
2002; Etienne-Manneville & Hall, 2001; Hall A., 2009). Thus, activation of Rho GTPases is 
necessary for signalling between cells and ECM and for maintenance of cell shape and 
associated focal adhesion complexes (Burridge & Wennerberg, 2004). 
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Furthermore, one main part of cellular crosstalk and adhesion is the signal transduction via 
the integrins and SFKs (Mainiero et al., 1995; 1997; Shaw et al., 1997; 2001). In addition, to 
the reduced gene expression of GTPases, we also identified that several integrin subunits 
(ITGA4, ITGA2 and ITGB1) are reduced in transcription by LysoPC exposition in a 
concentration-dependent manner (Alexander M. et al., 2010). Thus, one can assume 
interplay between the LysoPC incubation and the altered adhesion, membrane morphology 
and gene expression of the examined melanoma cells. 
The exact signal pathway that is affected by LysoPC exposition has to be investigated in 
future analyses due to the fact that not only one or a few defined signal pathways are 
triggering the adhesion process via integrins (Figure 4). Nevertheless it is suggested that – 
due to the kind of deregulated genes – the ERK/MAPK pathway may be one key part of the 
promising antimetastatic effects initiated by LysoPC.  
Genes which are regulated in expression levels by the ERK/MAPK pathway could influence 
the processes of invasion and adhesion. It is not completely understood if ERK/MAPK is 
activated or inhibited by LysoPC but specific kinases such as the dual-specificity 
phosphatase 1 (DUSP1) – a member of the threonine-tyrosine dual-specificity phosphatases - 
are deregulated by LPC treatment. Several members of the dual-specificity phosphatase 
(DUSPs) family are able to dephosphorylate MAPK isoforms with different specificity, 
cellular and tissue localization (Bermundez et al., 2010; Calvisi et al., 2008; Liu et al., 2007). 
The MAP kinases phosphatase (MKP) DUSP1/MKP-1 was shown to dephosphorylate ERKs 
(extracellular-regulated kinases), JNK and p38MAPKs (Liu et al., 2007). DUSP1 displays a 
rather broad specificity for inactivation of the ERK, p38 and JNK MAP kinases (Keyse, 2008). 
In addition, DUSP1 has detectable binding to ERK in vivo and is suggested to act as a 
positive activator of ERK in EGFR-mutant lung cancer cell lines independent of the ability to 
bind to ERK (Britson et al., 2009). Recent findings support the involvement of DUSPs in 
cancer progression and resistance (Bermundez et al., 2010) due to the fact that abnormalities 
in MAPK signalling have important consequences for processes critical to the development 
and progression of human cancer.   
LysoPC exhibit a comparable chemical structure to the experimental anticancer drugs 
miltefosine and edelfosine (Figure 5). The treatment of cancer cells with those 
alkylphosphocholines (APCs), which are able to incorporate into specific membrane 
compartments can disturb the well balanced and organized lipid network and thus 
influence the signalling of associated proteins. Such effects were reported for edelfosine and 
miltefosine, which are known to induce changes in receptor interaction and consequently 
signalling processes (Ausili et al., 2008; Gajate et al., 2009; Mollinedo & Gajate, 2010).  
Since LysoPC possess a remarkably rapid uptake in the membranes of cancer cells, a 
comparable cellular mechanism by the critical alteration of the integrity and functionality of 
specific membrane microdomains could be hypothesized for LysoPC with regard to the 
global gene expression data. Although LysoPC possesses an evident similarity in chemical 
structure compared to the APCs, LysoPC seems to activate different signalling pathways. 
One difference is that exposition with edelfosine leads to selective promotion of apoptosis in 
leukemic cells (Mollinedo et al., 1997; Gajate et al., 2000; 2004).  
Edelfosine was tested as a pharmaceutical compound against prostate cancer (Berdel et al., 
1981), human brain tumors, lung tumors and other cancer types (Berdel et al. 1984; Denizot 
et al., 2001; Haugland et al., 1999; Houlihan et al., 1987; Kosano & Takatani, 1988; Ausili et 
al., 2008). In detail, edelfosine exposition leads to accumulation in lipid rafts (van der Luit et 
al., 2002; Gajate et al., 2004) and to a reorganization of the lipid and protein composition of 
 
www.intechopen.com























Fig. 5. Chemical structures of: Lysophosphatidylcholine (1), Miltefosine (2), Edelfosine (3) 
and Ilmofosine (4). 
membrane caveolae (Gajate et al., 2004; Zaremberg et al., 2005; Gajate & Mollinedo, 2007). In 
a multiple myeloma animal model, oral administration of edelfosine showed a potent in 
vivo anti-myeloma activity and the drug accumulated preferentially in the tumor 
(Mollinedo et al., 2010). These data suggest that edelfosine incorporation in lipid rafts leads 
to a redistribution of sterols from the plasma membrane (Zaremberg et al., 2005). The 
redistribution of a major lipid raft component - they consist of cholesterol, glycolipids und 
sphingolipids - is likely to alter the biophysical properties of the lipid raft microdomain with 
putative important consequences for cell fate, due to the fact that the association of raft-
targeted proteins is strongly assumed to be altered. However, there are no data available 
how edelfosine affects the integrin status of tumor cells. 
In addition, the APC analog miltefosine (hexadecylphosphocholine) acts as another 
membrane-directed anti-tumoral and also anti-leishmanial drug (Santa-Rita et al., 2004). It 
activates anti-tumor effects against a broad spectrum of established tumor cell lines and 
solid tumors (Boggs et al., 1998; Wieder et al., 1998; Rybczynska et al., 2001; Jendrossek et al., 
2002). Initial clinical studies have shown promising results: for example, miltefosine may be 
used for the treatment of cutaneous metastases of mammary carcinomas (Clive et al., 1999; 
Jimenez-Lopez et al., 2010).  
Presently it remains open whether the antimetastatic effects and the serious affect on 
integrin activity by LysoPC are in line or on a comparable mechanistic level with the APC 
membrane effects. Future studies will provide insight into the hypotheses on membrane 
effects and the consequences for integrin localization and signalling. However, the non-
competitive influence on the integrin activity by changing the lipid microenvironment 
appears as an interesting approach to interfere with integrin function in tumor cell 
metastasis. 
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The mortality rate of melanoma diseases is to a great extent related to the high tendency to 
form metastases via the lymph and blood system. An increasing insight into the molecular 
mechanisms of hematogenous metastasis offers new therapeutic options to interfere with 
the metastatic spread. Cellular adhesion receptors appear as attractive targets in that 
context, since adhesion molecules mediate several key events to allow the tumor cells the 
survival in the blood system and the settlement in the vascular bed of distant organs.  
For a competitive blockade of the adhesion receptor function, heparin or non-
anticoagulative heparin products possess most promises, since heparin is clinically accepted 
as anticoagulant and numerous preclinical data confirm the capacity of heparin to interfere 
with the selectins and selected integrins.  
A novel strategy refers to a non-competitive influence on the adhesion receptors. A recent 
example is given by studies using LysoPC to melanoma cells, which drastically reduced the 
binding capacity of the integrin VLA-4 and thus, metastatic rate in mice. Although the exact 
molecular mechanisms are not fully elucidated, this might open new potential therapeutic 
options to reduce metastasis by interfering with adhesion molecules at the signalling level.  
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